Pharmaceutical major Cipla announced that its wholly-owned US subsidiary, InvaGen Pharmaceuticals Inc., has received one inspectional observation in Form 483 from the United States Food and Drug Administration (USFDA).
The observation followed a routine current Good Manufacturing Practices (cGMP) Inspection conducted at InvaGen's manufacturing facility located in Central Islip, Long Island, New York, USA. The inspection took place from July 13 to July 17, 2026 (EDT).
In response to the finding, Cipla stated its commitment to working closely with the USFDA. The company plans to address the single observation comprehensively within the stipulated timeframe.
Following the news, Cipla shares experienced a slight dip, closing 0.77% lower at Rs 1418.40 on Friday, compared to the previous close of Rs 1429.45.